US 7,601,870 B2
Substituted aniline derivatives
Christian Wenzel Tornøe, København (Denmark); Mario Rottländer, Greve (Denmark); Daniel Rodriguez Greve, Stenløse (Denmark); Nikolay Khanzhin, Humlebaek (Denmark); Andreas Ritzén, Vanløse (Denmark); and William Patrick Watson, Vanløse (Denmark)
Assigned to H. Lundbeck A/S, Valby-Copenhagen (Denmark)
Filed on Dec. 20, 2005, as Appl. No. 11/312,664.
Application 11/312664 is a continuation of application No. PCT/DK2005/000560, filed on Sep. 02, 2005.
Claims priority of provisional application 60/609856, filed on Sep. 13, 2004.
Claims priority of application No. 2004 01394 (DK), filed on Sep. 13, 2004.
Prior Publication US 2006/0155121 A1, Jul. 13, 2006
Int. Cl. C07C 233/05 (2006.01); A61K 31/65 (2006.01)
U.S. Cl. 564—219  [564/48; 564/57; 564/188; 564/189; 564/190; 564/220; 564/221; 514/596; 514/626] 9 Claims
 
1. A compound having formula I:

OG Complex Work Unit Drawing
wherein:
Z is O or S;
q is 0;
R1 and R2 are each independently selected from the group consisting of halogen, cyano, amino, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Aryl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yloxy, C3-8-cycloalk(en)yloxy, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy;
R3 is selected from the group consisting of C1-8-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Aryl-C1-6-alk(en/yn)yl, Aryl-C3-8-cycloalk(en)yl, Aryl-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, amino-C1-6-alk(en/yn)yl, amino-C3-8-cycloalk(en)yl, amino-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yloxy-C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yloxy-C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yloxy-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl and halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl; and
R4 is selected from the group consisting of halogen, cyano, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Aryl, Aryl-C3-8-cycloalk(en)yl, Aryl-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, NR5R6 and R7NH—C1-6-alk(en/yn)yl;
wherein:
R5 and R6 are each independently selected from the group consisting of hydrogen, Aryl-C1-6-alk(en/yn)yl, Aryl-C3-8-cycloalk(en)yl, Aryl-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6alk(en/yn)yl, with the proviso that R5 and R6 can not both be hydrogen; and
R7 is selected from the group consisting of C1-6-alk(en/yn)yl; C3-8-cycloalk(en)yl, C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Aryl, halo-C1-6-alk(en/yn)yl, halo-C3-8-cycloalk(en)yl, halo-C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl, Aryl-C1-6-alk(en/yn)yl, and Aryl-C3-8-cycloalk(en)yl;
with the proviso that the compound of formula I is not N-(4-Bromo-2,6-dimethyl-phenyl)-2-cyclopentyl-acetamide;or a pharmaceutically acceptable salt thereof.